LPARFS
BMRN icon

Leverage Partners Absolute Return Fund SPC’s BioMarin Pharmaceuticals BMRN Stock Holding History

Leverage Partners Absolute Return Fund SPC’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,800
Closed -$237K – 35
2022
Q3 		$237K Buy
+2,800
New +$249K 0.3% 35

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Leverage Partners Absolute Return Fund SPC's BMRN Position: Q4 2022 in Review

Leverage Partners Absolute Return Fund SPC sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 2,800 shares — an estimated $237K sold.

Leverage Partners Absolute Return Fund SPC first reported a position in BMRN in Q3 2022 and held it in 1 quarter. The position peaked at $237K in Q3 2022. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

  • Leverage Partners Absolute Return Fund SPC reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Leverage Partners Absolute Return Fund SPC sold 2,800 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $237K.
  • Leverage Partners Absolute Return Fund SPC first reported a position in BioMarin Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Leverage Partners Absolute Return Fund SPC's BioMarin Pharmaceuticals position peaked at $237K in Q3 2022.
  • 580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Leverage Partners Absolute Return Fund SPC's 13F filing for Q4 2022, filed 7 Feb 2023.